
|Videos|April 24, 2017
Biosimilars in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
FDA Approves Rucaparib for the Treatment of Adults With mCRPC
3
Notable Updates in Medication Therapy Management in 2025
4
Early Signals Before Myeloma: Real-World Data Reveal Missed Opportunities for Earlier Diagnosis
5












































































































































































































